Papillary renal cell carcinoma

A review of the current therapeutic landscape

Giulia Courthod, Marcello Tucci, Massimo Di Maio, Giorgio V. Scagliotti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is the most common cancer of the kidney and accounts for 2-3% of all adult malignancies. Clear cell carcinoma represents the most common histologic subtype, while papillary Renal Cell Carcinoma (pRCC) accounts for 10-20% of all renal cell cancers. While the inactivation of VHL gene can be found in the majority of clear cell carcinomas, different molecular mechanisms are involved into pRCC biology. Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases. Several agents, including anti-VEGF drugs and mTOR inhibitors, are possible options in the treatment of advanced and metastatic pRCC, following the demonstration of efficacy obtained in clinical trials including all RCC histologic subtypes. However, data specifically obtained in the subgroup of patients affected by pRCC are limited and not conclusive. Several ongoing trials are evaluating the efficacy of targeted therapy in papillary form. However, more rationale approaches based on molecular studies would help improving the outcome of these patients. Among others, MET inhibitors and targeted immunotherapy are promising new strategies for hereditary and sporadic disease. This review summarizes current knowledge on pRCC tumorigenesis and discusses recent and ongoing clinical trials with new therapeutic agents.

Original languageEnglish
Pages (from-to)100-112
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume96
Issue number1
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Renal Cell Carcinoma
Therapeutics
Clinical Trials
Carcinoma
Inborn Genetic Diseases
Kidney Neoplasms
Gene Silencing
Oncogenes
Immunotherapy
Vascular Endothelial Growth Factor A
Cell Biology
Carcinogenesis
Mutation
Pharmaceutical Preparations

Keywords

  • MET inhibitors
  • MET mutations
  • Papillary renal cell carcinoma
  • Targeted immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Papillary renal cell carcinoma : A review of the current therapeutic landscape. / Courthod, Giulia; Tucci, Marcello; Di Maio, Massimo; Scagliotti, Giorgio V.

In: Critical Reviews in Oncology/Hematology, Vol. 96, No. 1, 01.10.2015, p. 100-112.

Research output: Contribution to journalArticle

Courthod, Giulia ; Tucci, Marcello ; Di Maio, Massimo ; Scagliotti, Giorgio V. / Papillary renal cell carcinoma : A review of the current therapeutic landscape. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 96, No. 1. pp. 100-112.
@article{eda50467afb04cdf9020d69c1694b94d,
title = "Papillary renal cell carcinoma: A review of the current therapeutic landscape",
abstract = "Renal cell carcinoma (RCC) is the most common cancer of the kidney and accounts for 2-3{\%} of all adult malignancies. Clear cell carcinoma represents the most common histologic subtype, while papillary Renal Cell Carcinoma (pRCC) accounts for 10-20{\%} of all renal cell cancers. While the inactivation of VHL gene can be found in the majority of clear cell carcinomas, different molecular mechanisms are involved into pRCC biology. Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases. Several agents, including anti-VEGF drugs and mTOR inhibitors, are possible options in the treatment of advanced and metastatic pRCC, following the demonstration of efficacy obtained in clinical trials including all RCC histologic subtypes. However, data specifically obtained in the subgroup of patients affected by pRCC are limited and not conclusive. Several ongoing trials are evaluating the efficacy of targeted therapy in papillary form. However, more rationale approaches based on molecular studies would help improving the outcome of these patients. Among others, MET inhibitors and targeted immunotherapy are promising new strategies for hereditary and sporadic disease. This review summarizes current knowledge on pRCC tumorigenesis and discusses recent and ongoing clinical trials with new therapeutic agents.",
keywords = "MET inhibitors, MET mutations, Papillary renal cell carcinoma, Targeted immunotherapy",
author = "Giulia Courthod and Marcello Tucci and {Di Maio}, Massimo and Scagliotti, {Giorgio V.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2015.05.008",
language = "English",
volume = "96",
pages = "100--112",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Papillary renal cell carcinoma

T2 - A review of the current therapeutic landscape

AU - Courthod, Giulia

AU - Tucci, Marcello

AU - Di Maio, Massimo

AU - Scagliotti, Giorgio V.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Renal cell carcinoma (RCC) is the most common cancer of the kidney and accounts for 2-3% of all adult malignancies. Clear cell carcinoma represents the most common histologic subtype, while papillary Renal Cell Carcinoma (pRCC) accounts for 10-20% of all renal cell cancers. While the inactivation of VHL gene can be found in the majority of clear cell carcinomas, different molecular mechanisms are involved into pRCC biology. Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases. Several agents, including anti-VEGF drugs and mTOR inhibitors, are possible options in the treatment of advanced and metastatic pRCC, following the demonstration of efficacy obtained in clinical trials including all RCC histologic subtypes. However, data specifically obtained in the subgroup of patients affected by pRCC are limited and not conclusive. Several ongoing trials are evaluating the efficacy of targeted therapy in papillary form. However, more rationale approaches based on molecular studies would help improving the outcome of these patients. Among others, MET inhibitors and targeted immunotherapy are promising new strategies for hereditary and sporadic disease. This review summarizes current knowledge on pRCC tumorigenesis and discusses recent and ongoing clinical trials with new therapeutic agents.

AB - Renal cell carcinoma (RCC) is the most common cancer of the kidney and accounts for 2-3% of all adult malignancies. Clear cell carcinoma represents the most common histologic subtype, while papillary Renal Cell Carcinoma (pRCC) accounts for 10-20% of all renal cell cancers. While the inactivation of VHL gene can be found in the majority of clear cell carcinomas, different molecular mechanisms are involved into pRCC biology. Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases. Several agents, including anti-VEGF drugs and mTOR inhibitors, are possible options in the treatment of advanced and metastatic pRCC, following the demonstration of efficacy obtained in clinical trials including all RCC histologic subtypes. However, data specifically obtained in the subgroup of patients affected by pRCC are limited and not conclusive. Several ongoing trials are evaluating the efficacy of targeted therapy in papillary form. However, more rationale approaches based on molecular studies would help improving the outcome of these patients. Among others, MET inhibitors and targeted immunotherapy are promising new strategies for hereditary and sporadic disease. This review summarizes current knowledge on pRCC tumorigenesis and discusses recent and ongoing clinical trials with new therapeutic agents.

KW - MET inhibitors

KW - MET mutations

KW - Papillary renal cell carcinoma

KW - Targeted immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84942198664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942198664&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.05.008

DO - 10.1016/j.critrevonc.2015.05.008

M3 - Article

VL - 96

SP - 100

EP - 112

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -